GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound 24 [WO2020214734A1] | VT-3989
Compound class:
Synthetic organic
Comment: VT3989 is an orally bioavailable YAP/TAZ inhibitor that is proposed for antineoplastic potential. The structure is claimed in Vivace Therapeutics' patent WO2020214734A1 [2]. VT3989 inhibits YAP function and subsequent TEAD palmitoylation that would otherwise drive activation of transcriptional enhancer associate domain (TEAD) transcription factors that promote cell proliferation [3]. Hyperactivation of the Hippo-YAP/TAZ-TEAD pathway is implicated in tumour progression [1].
|
|
References |
1. Harvey KF, Zhang X, Thomas DM. (2013)
The Hippo pathway and human cancer. Nat Rev Cancer, 13 (4): 246-57. [PMID:23467301] |
2. Konradi AW, Lin TTLT. (2020)
Bicyclic compounds. Patent number: WO2020214734A1. Assignee: Vivace Therapeutics, Inc.. Priority date: 15/04/2020. Publication date: 22/10/2020. |
3. Ma S, Meng Z, Chen R, Guan KL. (2019)
The Hippo Pathway: Biology and Pathophysiology. Annu Rev Biochem, 88: 577-604. [PMID:30566373] |